NEW DELHI, Mar 21 : Union Minister of State (Independent Charge) for Science & Technology, Earth Sciences, and MoS PMO, Personnel, Public Grievances, Pensions, Atomic Energy and Space, Dr. Jitendra Singh said that India is steadily emerging as a robust pharma economy, which will not only accelerate future growth but also emerge as a significant contributor to the country’s overall GDP.
The minister emphasised that the growing strength of India’s pharmaceutical, medtech and manufacturing ecosystem is positioning the country as a key global manufacturing hub, particularly in high-quality, affordable healthcare solutions.
Delivering keynote address to a distinguished gathering at the “Healthcare Summit” organised by a leading English media house here, Dr. Jitendra Singh said that the discussions revolved around two central themes- “Made in India” and “Quality”. He highlighted that India’s healthcare and medtech ecosystem is undergoing a major shift, with a strong focus on global quality benchmarks, indigenous innovation, and integration of research with industry.
The Minister said that over the past decade, India has witnessed a remarkable transformation in healthcare, moving from a largely import-dependent system to one driven by indigenous capabilities. He recalled that earlier, critical medical devices, implants, and even advanced drugs were largely sourced from abroad, making treatment expensive and inaccessible for many. Today, India is developing its own antibiotics, vaccines, and advanced therapies, marking a decisive shift towards self-reliance.
Dr Jitendra Singh referred to the development of indigenous antibiotics and the rapid progress made during the COVID-19 pandemic, when India not only developed its own vaccines but also supplied them to several countries, reinforcing its role as a global healthcare partner. He said this transition reflects India’s growing credibility in both therapeutic and preventive healthcare.
The Minister also spoke about the emergence of cutting-edge technologies in India’s healthcare ecosystem, including gene therapy, with successful trials in conditions like haemophilia, as well as innovations in treatment for diseases such as sickle cell anaemia. He added that Indian institutions are now contributing to globally recognised research, with publications in leading international medical journals.
Highlighting the government’s push for quality standards, Dr Jitendra Singh said that “homegrown” products in India now match global benchmarks, with regulatory systems aligned to international standards. Through streamlined approval mechanisms and strengthened regulatory frameworks, indigenous medical devices such as stents, ventilators and diagnostic equipment are ensuring safety, efficacy, and affordability.
